title: Ocular myasthenia gravis after D-penicillamine administration.
abstract: A 68-year-old black woman who was put on D-penicillamine therapy (250-500 mg per day, total dose 15 g) for rheumatoid arthritis developed ocular myasthenia gravis. Two weeks after she discontinued D-penicillamine her signs and symptoms cleared with no other treatment. Review of previous cases and possible immunological mechanisms are discussed.
authors.affiliation: William and Anna Goldberg Glaucoma Service, Thomas Jefferson University, Philadelphia, PA 19107.
authors.forename: L J
authors.initials: LJ
authors.lastname: Katz
authors.forename: R L
authors.initials: RL
authors.lastname: Lesser
authors.forename: J R
authors.initials: JR
authors.lastname: Merikangas
authors.forename: J P
authors.initials: JP
authors.lastname: Silverman
mesh_terms: D000368:Aged; D001763:Blepharoptosis / Q000139:chemically induced*; D004172:Diplopia / Q000139:chemically induced*; D005260:Female; D006801:Humans; D009157:Myasthenia Gravis / Q000139:chemically induced*; D010396:Penicillamine / Q000009:adverse effects*
chemical_list: D010396:Penicillamine